Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Vapocoolant Spray to Reduce Pain With Nexplanon Insertion

NCT06933381 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.

Interventions

  • OTHER Placebo
  • DEVICE Vapocoolant spray

Study Locations (3)

Hawaii

  • Queens Medical Center POB 2 Suite 402 — Honolulu
  • Queens Medical Center POB1 Clinic 1004 — Honolulu
  • Women's Center Queen's North Hawai'i Community Hospital Suite #124 and #120 — Waimea

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2025-06-16
Est. Completion 2026-05-01
Phase NA

Sponsor

Queen's Medical Center

6 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06933381

The ClinicalTrials.gov registry entry for NCT06933381 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Queen's Medical Center, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Reducing Pain With Nexplanon Implant Insertion appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06933381 reports 3 study locations spanning 1 distinct geographic area — top geographies include Hawaii. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06933381 about?

NCT06933381 is a clinical study titled "Vapocoolant Spray to Reduce Pain With Nexplanon Insertion". The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.

What is the current status of trial NCT06933381?

This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-06-16. Estimated completion is 2026-05-01.

What conditions does trial NCT06933381 study?

This clinical trial studies the following conditions: Reducing Pain With Nexplanon Implant Insertion. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06933381?

The interventions under investigation include: Placebo (OTHER), Vapocoolant spray (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06933381?

This trial is sponsored by Queen's Medical Center, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06933381 being conducted?

This trial has 3 study locations across Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial